Following the initial discovery of RAC1B in CRC tumor samples, clinical investigations found that RAC1B expression in CRC tumors is significantly associated with BRAF mutation status, where approximately 80% of BRAF-mutated CRC tumors also overexpress RAC1B; however, tumors that do not have BRAF mutations can also overexpress RAC1B [92]. Here, BRAF is linked to neoplasm.